
Electronic Records & Signatures
Explore this topic in more depth to build a complete picture of your quality and compliance operations.
ExploreThe regulated digital equivalent of a handwritten signature: uniquely attributable to one person, linked to the signed record, captured with meaning and timestamp, and verifiable on inspection.
Electronic signatures are how regulated approvals move from paper to digital without losing accountability. Done well, they replace ink-and-paper at scale. Done poorly, they create inspection findings that affect every signed record they touched.

An electronic signature is the regulated digital equivalent of a handwritten signature. It's the logical association of one person's identity to a specific action on an electronic record, captured with intent, meaning, and timestamp, and bound to the record so it can't be detached or transferred.
In the U.S., 21 CFR Part 11 defines the criteria. In the EU, Annex 11 and eIDAS (Regulation EU 910/2014) cover overlapping ground. ISO 13485 §4.2.4–4.2.5 addresses signature controls for medical device QMS records. Each framework asks similar questions: who signed, when, for what purpose, and how do we know it was actually that person?
Electronic signatures cover three categories of action in regulated systems. Approval releases a record into a regulated decision: batch release, document approval, CAPA closure. Review captures a reviewer's sign-off that they checked the work. Responsibility or authorship means the signer takes accountability for the content. Each carries a different meaning that has to be captured.
A compliant electronic signature is more than clicking 'I agree'. It involves re-authentication, role-appropriate authority, meaning capture, record binding, and an audit trail entry — all governed by §§11.50, 11.70, 11.100, 11.200, and 11.300 for FDA-regulated systems.
Electronic signatures are how regulated approvals move from paper to digital. They underpin every batch release, every CAPA closure, every document approval, every change request authorisation. The integrity of those approvals depends entirely on the signature being what it claims to be.
FDA's chromatography enforcement actions from 2017 onward produced dozens of warning letters citing electronic signature failures. Shared analyst accounts. Signatures without meaning. Signatures separable from the record. Weak passwords. Biometric signatures without the required controls. Each failure invalidates not just the signature but the regulatory decision it supported.
Inspector perspective: the question inspectors keep coming back to is whether a specific person, with the authority to do this, actually applied this signature with the intent to do what the system says they did. If any link in that chain breaks — shared account, missing meaning, signature that could be moved to another record — the signature isn't evidence of anything.
Electronic signature requirements span multiple frameworks; the U.S. and EU citations most commonly seen in inspection findings:
A complete electronic signature event captures the following, all at the moment of signing:
The programs that hold up under inspection share these patterns:
A single 'lab' or 'analyst' account used by multiple people violates §11.100 (uniqueness) and §11.10(d) (limited access). A signature applied from a shared account isn't legally tied to a specific individual. Recalls and consent decrees have been driven by exactly this pattern. Eliminate it before it becomes your finding.
Complere is built around regulated approvals. Electronic signatures aren't an add-on — they're how documents get released, CAPAs get closed, changes get authorised, audit findings get signed off, and risk assessments get approved. Every signature your team applies carries the controls regulators expect, every time.
When someone on your team signs something, it's tied to their unique authenticated account — never a shared "lab" or "analyst" login. Complere doesn't let users share accounts; every login belongs to one person. Logging in uses two distinct identification components, and if your user steps away and comes back, they re-authenticate. Before applying the signature, your user picks what it means — review, approval, responsibility, or authorship — and that meaning travels with the signature. The signature is bound to the specific record it was applied to, so no one can lift it and move it somewhere else.
Authority is checked at the moment of signing. Roles decide who can apply which meaning to which record type; the platform confirms your user actually holds that authority before the signature lands. Signature requirements come from controlled templates per record type, so a CAPA closes the same way every time, and a document approval follows the same rules every time — your team isn't reinventing the control set per record.
When records get exported or printed, the signature shows up on the output: signer's name, the moment they signed, and what they signed it for. Every signing event is captured in the record's history with all four elements (who, what, when, why), so when an inspector asks to see the signing history on a release decision, your team produces it without scrambling.
What stays with your team: the SOPs that say who can sign for what, the training that makes sure your users understand the weight of an electronic signature, the periodic review of signing patterns for anything unusual, and the IT discipline that keeps unique accounts unique. Complere makes the technical controls reliable; the program that wraps them is yours.
Common questions about Electronic Signature sourced from regulatory references and inspection patterns.
Five things, drawn from 21 CFR §§11.50, 11.70, 11.100, 11.200, 11.300: (1) unique to one person and not reassigned; (2) at least two distinct identification components for non-biometric signatures; (3) the signature record captures the printed name of the signer, date and time, and meaning (review, approval, responsibility); (4) the signature is linked to the record so it can't be excised or transferred; (5) the firm has certified to FDA that its electronic signatures are intended as legally binding equivalents of handwritten signatures.
Under eIDAS in the EU and ESIGN in the U.S. consumer context — sometimes, depending on intent and context. Under 21 CFR Part 11 for GxP records — no. Part 11 requires unique attribution, two-factor identification components, meaning capture, and record binding. A typed name in an email doesn't carry any of those by default.
Under §11.200(a)(1), non-biometric electronic signatures used during a continuous session work this way: the first signing uses all electronic signature components; subsequent signings in the same session use at least one component (the other being implicit through the session). When the user leaves the session and returns, full re-authentication is required again. The definition of "continuous session" is up to the firm but should sit in an SOP.
An electronic signature (Part 11 sense) is a logical association of a signer's identity to a record with intent. A digital signature is one technical implementation that uses cryptographic methods (PKI, hash) to create a tamper-evident binding. All digital signatures are electronic signatures; not all electronic signatures are digital signatures. Open systems under §11.30 require digital signatures plus encryption; closed systems under §11.10 can use other authentication mechanisms.
Under §11.50, the signature record has to display the meaning associated with the signature: review, approval, responsibility, authorship — whichever applies. The meaning has to be linked to the signature event in the record. A signature without meaning fails §11.50 even if all other controls are in place. The captured meaning is also part of the audit trail under §11.10(e).
Recurring patterns: shared accounts violating §11.100 unique-signature requirement; signatures applied without meaning capture, failing §11.50; signatures not bound to the record (excisable or transferable), failing §11.70; passwords shared or written down, failing §11.300; biometric signatures without controls against use by anyone other than the genuine owner, failing §11.200(b). The chromatography enforcement actions that ran from 2017 onward drove many of these.
No. Shared accounts fail §11.100 (uniqueness) and §11.10(d) (limiting access to authorised individuals). A signature applied from a shared account isn't legally tied to a specific individual. This pattern alone has driven product recalls and consent decrees. The fix is unique accounts only, with formal provisioning and deprovisioning.
No. eIDAS (Regulation EU 910/2014) governs general electronic transactions in the EU and defines simple, advanced, and qualified electronic signatures. For GxP records, EU GMP Annex 11 plus Annex 16 plus Chapter 4 apply alongside eIDAS. Most regulated firms operating in the EU map their Part 11 controls onto Annex 11 expectations and use eIDAS qualified-signature where business-legal context requires it.
Explore related topics, modules, and compliance resources for a deeper understanding of your quality system.

Explore this topic in more depth to build a complete picture of your quality and compliance operations.
Explore
Explore this topic in more depth to build a complete picture of your quality and compliance operations.
Explore
Explore this topic in more depth to build a complete picture of your quality and compliance operations.
ExploreWalk through Complere's role-based e-signature: identity, meaning, timestamp, record binding, and audit trail across documents, CAPA, change requests, audits, events, and risk assessments.